1
Clinical Trials associated with V001-DLL3 / RecruitingEarly Phase 1IIT A Phase I Study of the In Vivo CAR-T Platform for Treating Advanced Malignant Tumors Based on Target Screening
This is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3, etc.) in patients with advanced malignant tumors.
100 Clinical Results associated with V001-DLL3
100 Translational Medicine associated with V001-DLL3
100 Patents (Medical) associated with V001-DLL3
100 Deals associated with V001-DLL3